Schedule 13D ownership disclosure
TriSalus Life Sciences Inc
Common Stock, $0.0001 par value · CUSIP: 89680M101
Event date: 2025-04-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Frankenius Equity ABReported CIK 0001988262
Shares: 6,732,516.00 · Class: 20.5%
- Paul Frankenius
Shares: 6,732,516.00 · Class: 20.5%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001415889-25-011783
- Form type
- SCHEDULE 13D/A
- Filer
- Frankenius Equity AB
- CIK
- CIK 1988262
- Filed
- May 02, 2025
- Reporting period
- Apr 30, 2025
- Description
- Schedule 13D beneficial ownership